A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene

NCT03605069 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Low enrollment

Conditions

Epidermolysis Bullosa Dystrophica, Recessive
Epidermolysis Bullosa Dystrophica, Dominant

Interventions

DRUG: QR-313
DRUG: Placebo

Sponsor

Phoenicis Therapeutics